ESCMID


Final Programme

European Congress of
Clinical Microbiology
and Infectious Diseases

ECCMID

Lisbon, Portugal
23 – 26 April 2022





32nd

www.eccmid.org

Introduction

Welcome Address

Dear friends and colleagues,

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is delighted to invite you to take part at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022), which will be held from Saturday 23 to Tuesday 26 April 2022, in a hybrid format both online and onsite in Lisbon, Portugal.

ECCMID is the leading and the largest educational platform for specialists in clinical microbiology, infectious disease, infection prevention, infection control and public health. ECCMID 2022 will offer excellent opportunities to corporate partners to showcase their latest findings, share their experiences and knowledge and demonstrate practical techniques and guidance.

Last year, for the first time, we explored a fully virtual delivery of ECCMID to maximise our accessibility in a time of tremendous uncertainty during the COVID-19 pandemic. We saw the opportunity to bring together participants from all around the globe, focusing on sharing scientific information. As we strive to increase the excellence of our annual congress constantly, we continue to develop our hybrid format for ECCMID. This year we are excited to return to hosting an onsite congress in Lisbon, Portugal bringing back the personal interaction that has been sorely missed. However, the addition of an online platform ensures that we retain the flexibility and accessibility of the scientific content for all attendees regardless of geographic or travel limitations.

The ECCMID Programme Committee is working tirelessly to create a comprehensive and timely programme covering the entire range of ECCMID topics with high-level speakers. Participants will have the opportunity to meet researchers from many parts of the world to discuss methods, results and the impact on clinical and laboratory practice. As in previous years, young professionals will also have the opportunity to discuss their ideas and projects with renowned experts in a variety of interactive sessions that also provide superb networking opportunities. This year ECCMID will again feature pipeline corners where innovative companies and research groups will be offered a platform to present their early-stage antimicrobial therapies, diagnostic products in development, and research funding opportunities to a wider audience. This will be complemented by scientific content co-developed with the industry such as the integrated symposia.

Last year we expanded our programme to include a series of "Pre-ECCMID Days" that took place leading up to the congress and covered a variety of hot topics, including COVID-19, AMR and Vaccines. These were well attended individual learning days that increased the breadth of ECCMID and allowed for special topics to be brought to the forefront of scientific discussions. We are continuing this initiative this year while addressing key themes that will be further covered and built upon during the congress itself.

Other new features from ECCMID 2021 that will be returning this year will be the Keynote Fireplace sessions where ECCMID keynote speakers meet with a small group of participants to enter a more in-depth discussion on their keynote lecture. Additionally, the infectious disease-themed Escape Room will be reprised and updated as an immersive interactive addition. We also invite our participants to take part in our ECCMID Art Gallery, showcasing the creativity of our community.

ECCMID 2022 will enable our community to discuss, network, develop and share knowledge that is imperative for our discipline. The scientific programme will highlight the latest scientific achievements and will create a comprehensive intellectual and operational environment for the acquisition of knowledge, skills and clinical judgement.

The venues in Lisbon offer all modern amenities required for the successful organisation of our congress and is reachable by public transport from the city centre. After a day full of inspiring sessions and fruitful discussions, we hope that you will have time to explore Lisbon, a cosmopolitan city with a rich history and culture. We look forward to seeing you both onsite in Lisbon and online! Thank you for again making this congress one of the top scientific events of the year.

Maurizio Sanguinetti
ESCMID President



Jesús Rodríguez-Baño
ESCMID Immediate Past President and Guidelines Officer



Jacob Moran-Gilad
ECCMID Programme Director



Committees

ESCMID Executive Committee



Maurizio Sanguinetti
ESCMID President
Rome, Italy



Annelies Zinkernagel
ESCMID President-elect and Secretary General
Zurich, Switzerland



Jesús Rodríguez-Baño
Immediate Past President and Guidelines Officer
Seville, Spain



Jon S. Friedland
Scientific Affairs Officer
London, United Kingdom



Alexander W. Friedrich
Treasurer and Financial Support Officer
Groningen, Netherlands



Robert Leo Skov
Education Officer
Copenhagen, Denmark



Önder Ergönül
Communications and Publications Officer
Istanbul, Turkey



Emmanuelle Cambau
Professional Affairs Officer
Paris, France

ESCMID Ad-hoc Executive Committee Members



Jacob Moran-Gilad
ECCMID Programme Director
Be'er Sheva, Israel



Leonard Leibovici
CMI Editor-in-Chief
Petah-Tiqva, Israel



Luigia Scudeller
ESCMID Guidelines Director
Bologna, Italy



Christian G. Giske
EUCAST Chairperson
Stockholm, Sweden



Evelina Tacconelli
EUCIC Chairperson
Verona, Italy



Murat Akova
ESCMID Membership Counsellor (EMeC)
Ankara, Turkey

Committees

ESCMID Education Subcommittee (ES)
Robert Skov, Copenhagen, Denmark, *Chairperson*
Nicholas Power, Dublin, Ireland
Sarah Delliere, Paris, France
Kaisu Hellevi Rantakokko-Jalava, Turku, Finland
Giovanni Delogu, Rome, Italy
Gülsen Özkaya Sahin, Lund, Sweden
Katja Seme, Ljubljana, Slovenia
Siri Goepel, Tuebingen, Germany
Simona Ruta, Bucharest, Romania

ESCMID Publication Subcommittee (PS)
Önder Ergönül, Istanbul, Turkey, *Chairperson*
Leonard Leibovici, Petah-Tiqva, Israel
Alexander J. Smith, Oxford, United Kingdom

ESCMID Scientific Affairs Subcommittee (SAS)
Jon S. Friedland, London, United Kingdom, *Chairperson*
Mary Horgan, Cork, Ireland
Holger Rohde, Hamburg, Germany
Zeno Bisoffi, Verona, Italy
Silvio Brugger, Zurich, Switzerland
Bettie Voordouw, Culemborg, Netherlands
Pontus Naucler, Stockholm, Sweden
Joanna Maria Zajkowska, Białystok, Poland
Alvaro Pascual Hernandez, Seville, Spain
Katharina Last, Homburg, Germany

ESCMID Professional Affairs Subcommittee (PAS)
Clinical Microbiology
Emmanuelle Cambau, Paris, France, *Chairperson*
Makeda Semret, Montreal, Canada
Karl Gustaf Kristonsson, Reykjavik, Iceland
Birgit Willinger, Vienna, Austria
Olivier Denis, Brussells, Belgium
UEMS MM Section representative:
Truls Michael Leegaard, Lørenskog, Norway
Infectious Diseases
Özlem Kurt Azap, Ankara, Turkey
Anna Checkley, London, United Kingdom
Rita Murri, Rome, Italy
Sipho Kenneth Dlamini, Cape Town, South Africa
UEMS ID Section representative:
Jean Paul Stahl, Grenoble, France

Parity Commission (PC)
Emmanuelle Cambau, Paris, France, *Chairperson*
Agnes Maria Sonnevend, Pecs, Hungary
Onya Opota, Lausanne, Switzerland
Giulia De Angelis, Rome, Italy

Ethics Advisory Committee (EAC)
Aleksandra Barac, Belgrade, Serbia
Asma Nasim, Karachi, Pakistan
Elda Righi, Verona, Italy
Dafna Yahav, Petah-Tikva, Israel

Guidelines Subcommittee (GL-SC)
Luigia Scudeller, Bologna, Italy, *Guidelines Director*
Jesús Rodríguez-Baño, Seville, Spain, *Guidelines Officer*
Cihan Papan, Homburg, Germany
Effrossyni Gkrania-Klotsas, Cambridge, United Kingdom
Sarah Tschudin Sutter, Basel, Switzerland
Amel Lataief, Sousse, Tunisia
Khetam Hussein, Haifa, Israel
Jean Paul Stahl, Grenoble, France

Trainee Association of ESCMID (TAE)
Valentijn Schweitzer, Utrecht, Netherlands, *President*
Petar Velikov, Sofia, Bulgaria
Maria Joâo Lopes, Lisbon, Portugal
Sarah Dellière, Paris, France
Katharina Last, Homburg, Germany
Ivana Antal Antunović, Zagreb, Croatia
Anja Šterbenc, Ljubljana, Slovenia
Nicholas Power, Dublin, Ireland

ESCMID International Affairs Subcommittee (EIAS)
Nicola Petrosillo, Rome, Italy, *Chairperson*
Adrian John Brink, Cape Town, South Africa
Svetlana Rachina, Russian Federation
Mauricio J. Farfan, Santiago, Chile
Ramasubramanian Venkatasubramanian, Chennai, India
Seif Al-Abri, Muscat, Oman
Yunsong Yu, Hangzhou, China
Maria Eugenia Gutierrez Pimentel, Chiriqui, Panama
Adalat Abdullayev, Baku, Azerbaijan

ESCMID Study Groups

Anaerobic Infections (ESGAI)
www.escmid.org/ESGAI
Trefor Morris, Cardiff, United Kingdom

Antimicrobial Stewardship (ESGAP)
www.escmid.org/ESGAP
Jeroen Schouten, Nijmegen, Netherlands

Biofilms (ESGB)
www.escmid.org/ESGB
Gordon Ramage, Glasgow, United Kingdom

Bloodstream Infections, Endocarditis & Sepsis (ESGBIES)
www.escmid.org/ESGBIES
Willem Joost Wiersinga, Amsterdam, Netherlands

Brain Infections (ESGIB)
www.escmid.org/ESGIB
Matthijs Brouwer, Amsterdam, Netherlands

Clinical Parasitology (ESGCP)
www.escmid.org/ESGCP
Caroline Rönnberg, Stockholm, Sweden

Scientific Programme
Saturday, 23 April 2022

ID

SY001 **08:30 - 10:30** **Hall C**
Symposium

Infections in patients receiving new immunomodulatory therapies

Chairs *Oliver A. Cornely (Cologne, Germany)*
Carlota Gudiol (Barcelona, Spain)

S0001 **08:30** **Patients receiving immune check-point inhibitors**
Gil Redelman-Sidi (New York, United States)

S0002 **09:00** **Patients receiving CAR-T therapy**
Andrea Henden (Herston, Australia)

S0003 **09:30** **Non-neutropenic infection associated risk in patients with haematological malignancies**
Monica Slavin (Melbourne, Australia)

S0004 **10:00** **Patients receiving therapy for systemic or organ-specific autoimmune diseases**
Mario Fernandez Ruiz (Madrid, Spain)

ID

SY002 **08:30 - 10:30** **Hall G**
Symposium

Fungal infections from head to toe

Chairs *Anuradha Chowdhary (Delhi, India)*
Emmanuel Roilides (Thessaloniki, Greece)

S0005 **08:30** **Emerging treatment failure in dermatophytosis: genotyping and resistance testing of the *Trichophyton mentagrophytes* species complex**
Philipp Bosshard (Zurich, Switzerland)

S0006 **09:00** **Update on *Tinea capitis*: epidemiology, symptoms and treatment**
Pietro Nenoff (Mölbis, Germany)

S0007 **09:30** **Update on diagnosis and treatment of recurrent vulvovaginal candidiasis**
Riina Richardson (Manchester, United Kingdom)

S0008 **10:00** **The role of *Malassezia* in health and disease**
Ditte Marie Lindhardt Saunte (Roskilde, Denmark)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

PH

SY003 **08:30 - 10:30** **Hall I**
Symposium

Genomics underpin the clinical and public health management of tuberculosis

Chairs *Sebastien Gagneux (Basel, Switzerland)*
Robyn Lee (Toronto, Canada)

S0009 **08:30** **Understanding TB pathogenicity and host interactions using genomic approaches**
Stefan Niemann (Borstel, Germany)

S0010 **09:00** **Genomics in the diagnosis of drug resistance in TB**
Paolo Miotto (Milano, Italy)

S0011 **09:30** **Integrating genomics into TB management in an African setting**
Yonas Kassahun (Addis Ababa, Ethiopia)

S0012 **10:00** **New tools for genomic prediction and mapping of resistance in TB**
Timothy Walker (Ho Chi Minh City, Vietnam)

ID CM

SY004 **08:30 - 10:30** **Hall L**
Symposium

Challenges and opportunities in CM/ID training and practice

Chairs *Emmanuelle Cambau (Paris, France)*
Valentijn Schweitzer (Utrecht, Netherlands)

S0013 **08:30** **How to excel and become a leader in CM, ID or IC?**
Truls Michael Leegaard (Lørenskog, Norway)

S0014 **09:00** **Developing effective communication skills: social media and networking**
Muge Cevik (Edinburgh, United Kingdom)

S0015 **09:30** **Practising Clinical Microbiology in low-resource settings**
Makeda Semret (Montreal, Canada)

S0016 **10:00** **Practising Infectious Diseases in low-resource settings**
Sipho Kenneth Dlamini (Cape Town, South Africa)

Co-organised with: ESCMID Professional Affairs Subcommittee (PAS), Trainee Association of ESCMID (TAE)

Presentations in light grey were not registered at the time of publishing.

P1405 **Efficacy evaluation of an antimicrobial stewardship programme on antibiotic consumption and *C. difficile* infection rates in a tertiary hospital in Italy before and during COVID-19 pandemic**
E. Chiari (Brescia, Italy), E. Festa, G. Del Fabro, E. Van Hauermeiren, S. Lorenzotti, B. Saccani, P. Lanza, A. Matteelli, F. Castelli, L. Signorini*

P1406 **Understanding the barriers and drivers for antimicrobial stewardship experienced by health care practitioners when treating upper respiratory tract infections in Europe**
A.W. Van Der Velden (Utrecht, Netherlands), A. Altiner, A. Sessa, R. Kozlov, A. Shephard, A.B. Smith, S.Y. Essack*

P1407 **Trends of broad spectrum antibiotics consumption in Spain, 2012-19**
M. Cantero Caballero (Madrid, Spain), E. Jiménez Tejero, L.M. Parra Ramírez, Á. Asensio Vegas, R.M. Ortí Bordas, I. Salcedo Leal*

P1408 **Creation of a bone and joint infection multidisciplinary team in a distrital hospital: evaluation of the first months of activity**
C. Soeiro (Aveiro, Portugal), J. Velez, C. Coimbra, C. Malheiro, N. Kruptsala, M. Vieira, F. Freitas*

P1409 **Assessing the conversion of electronic patient records data into antibiotic stewardship quality indicators**
L. Renggli (Bern, Switzerland), C. Plüss-Suard, M. Gasser, B. Sonderegger, A. Kronenberg*

P1410 **Use of an antimicrobial stewardship smartphone app in hospitals: an international, multi-centre, cluster-randomised study**
R. Helou (Rotterdam, Netherlands), G. Catho, A. Peyravi Latif, J. Conly, T. Tängdén, B. Huttner, A. Verbon*

P1411 **The "BATMO" programme: effectiveness and outcome of an innovative anti-infectious prophylaxis scheme in patients undergoing allogenic haemopoietic stem cells transplantation**
B. Fumarola (Brescia, Italy), M. Lorenzo, G. Del Fabro, L. Signorini, S. Lorenzotti, M. Malagola, A. Turra, F. Castelli, D. Russo*

P1412 **Antimicrobial stewardship in intensive care units (ICU) of a private hospital in Brazil**
W. Freitas (Rio De Janeiro, Brazil), Vasconcelos De, M. Alves, Silvana, S. Nouér, Aranha*

P1413 **Characteristics of ceftriaxone prescription in a tertiary hospital in Portugal: opportunities for stewardship interventions**
A. Gorgulho (Cascais, Portugal), F. Cunha, E. Branco, A. Azevedo, F. Almeida, R. Duro, N. Pereira, P. Andrade, C. Alves*

P1414 **Impact of COVID-19 pandemic on quality indicators for appropriate antibiotic use**
B. Dietl (Barcelona, Spain), L. Boix-Palop, L. Gómez, P. Arcenillas, M. Xercavins, N. Sanmarti, Ú. Masats, C. Badia, J. Nicolás, E. Calbo*

P1415 ***Staphylococcus aureus* bacteraemia electronic reminder (SABER): infectious disease consultation rates and patient outcomes after implementation of an automated electronic medical record nudge**
A. Lepak (Madison, United States), J. Perzynski, S. Biswas, B. Schnapp, M. Brennan*

P1416 **Dalbavancin serums level in complicated cardiovascular infectiosn: a small case series from the Univeristy Hospital Schleswig Holstein, Campus Kiel**
A. Friedrichs (Kiel, Germany), C. Kujat, B. Steinborn, F. Soergel, M. Kinzig*

P1417 **Description of a novel information technology system (FATS) as an antimicrobial stewardship aid**
A. Bapat (London, United Kingdom), T. O'Neill, K. Kalia, L. Caldwell, F. Jimenez-England, N. Perera, N. Duncan, M. Andersson, J. Lambourne, L. Drumright, S. Agrawal*

P1418 **Effect of daily antibiotic stewardship ward rounds on adherence to local treatment guidelines and antibiotic consumption in a large university emergency department**
L. Arenz (Munich, Germany), A. Porger, A. Weber, J. Jung, H. Horns, S. Gscheidle, T. Weiglein, J. Pircher, M. Klein, R. Draenert*

P1419 **Factors contributing to decisions on antibiotic prescribing for suspected urinary tract infections in frail older adults: a qualitative study**
E.A.R. Hartman (Amsterdam, Netherlands), W.G. Groen, S.R. Heltveit-Olsen, M. Lindbæk, S. Høye, I. Skoglund, P.D. Sundvall, E. Snaebjörnsson Arnljots, R. Gunnarson, A. Kowalczyk, M. Godycki-Cwirko, K. Kosiek, T.N. Platteel, A.C. Van De Pol, T.J.M. Verheij, A.A. Monnier, C.M.P.M. Hertogh*

P1420 **Activities of cationic steroid antibiotics against *Myroides* spp., from Turkish hospitals**
E.S. Demir (Istanbul, Turkey), T. Eltimur, C. Bozkurt Güzel, O. Oyardi, A. Akçali, P.B. Savage*

P1421 **Pharmacist's role in antimicrobial stewardship: a qualitative study from India, South Africa and the United Kingdom**
E. Charani (London, United Kingdom), V. Nampoothiri, O. Mbamalu, M. Mendelson, S. Singh*

P1422 **Reductions in antibiotic prescribing in Australia during the SARS-CoV-2 pandemic: national prescribing data**
J. Skeggs (Clayton, Australia), A. Macphail, T. Korman, I. Woolley, J. Lau*

P1423 **GPPAS model: guiding the implementation of antimicrobial stewardship by general practitioner-pharmacist collaboration in Australian primary care**
S.K. Saha (Melbourne, Australia), D. Kong, K. Thursky, D. Mazza*

P1424 **Fluoroquinolone (FQ) use reduction using the CDC antibiotic use Option (AUO): restoring Gram-negative bacteria susceptibility to FQ**
G. Forrest (Chicago, United States), K. Mackay, C. Pfeiffer*

P1425 **Use of nudging strategies to develop a clinical microbiology antimicrobial stewardship framework**
L. Matukas (Toronto, Canada), M. Mcintyre, B. Langford, E. Leung, R. Haj, L. Taggart, A. Scherer, K. Brown*

P1426 **Assessing the use of forgotten antibiotics through the global point prevalence survey of antimicrobial consumption and resistance (Global-PPS)**
A. Versporten (Antwerp, Belgium), I. Pauwels, H. Goossens*

P1553 **Fungicidal activity of serum from patients on anidulafungin therapy against *Candida parapsilosis* and *Candida glabrata* isolates**
J. Meletiadis (Athens, Greece), M.I. Beredaki, M. Siopi, O. Apostolopoulou, G. Dimopoulos, S. Pournaras*

P1554 **The efficacy of ceragenins against first *Candida auris* strains isolated in Turkey**
B. Alkan (Istanbul, Turkey), O. Oyardi, S. Komec, G. Genc Erkose, G. Aygun, L. Teke, D. Turan, Z. Erturan, P. Savage, C. Bozkurt Guzel*

P1555 **Impact of early antifungal initiation on clinical outcomes in critically ill patients with candidaemia**
D. Holger (Detroit, United States), A. Lagnf, S. Alosaimy, N. Rebold, T. Morrisette, A. Belza, A. Kunz Coyne, A. El Ghali, D. Newlun, W. Kufel, K. Stover, M. Rybak*

P1556 **Ellagic acid, a new substance for treating *Candida* species**
J. Jun (Moroyama, Japan), T. Norihito, O. Hideaki, M. Shigefumi*

P1557 **Tolerability of pulse high dose liposomal amphotericin B as preemptive therapy in patients with high risk for intra-abdominal candidiasis. Preliminary report of LAMBDA Study: an ongoing phase II study**
B. Tazza (Bologna, Italy), M. Rinaldi, C. Bonazzetti, B. Granozzi, C. Solera Horna, N. Caroccia, M. Bartoletti, M. Giannella, P. Viale*

P1558 **Prospective study on posaconazol TDM in critically ill patients**
M. Göpfert (Hamburg, Germany), D. Wichmann, C. König, H. Jungen*

P1559 **Short course of antifungal therapy in non-complicated candidaemia: another case of less is more in the clinical setting?**
S. Tutino (Genoa, Italy), A. Santagostino Barbone, L. Mezzogori, F. Baldi, L. Labate, S. Dettori, C. Russo, D.R. Giacobbe, C. Dentone, L. Magnasco, M. Mikulska, L. Taramasso, A. Di Biagio, A. Vena, F. Bovis, M. Bassetti*

P1560 **Genome-scale metabolic model of the human pathogen *Candida auris*: computational approach to finding new drug targets**
R. Viana (Lisbon, Portugal), D. Couceiro, T. Carreiro, C. Souza, O. Dias, I. Rocha, C.M. Soares, M.C. Teixeira*

P1561 **Evaluation of the new VITEK-2 antifungal susceptibility system, AST-YS08 card with broth microdilution methods using clinical isolates of *Candida* species**
J.Y. Kim (Incheon, Korea, Republic of), H. Lee, G.H. Sung, H.K. Lee, J.H. Shin, C.H. Lee, S.W. Ryu*

P1562 **Oral ibrexafungerp outcomes in patients with invasive candidiasis and candidaemia from the FURI and CARES Studies**
O. Cornely (Cologne, Germany), P. Pappas, T. King, N. Azie, D. Angulo*

P1563 **COVID-19 associated mucormycosis (CAM) in Russian Federation: results of prospective multi-centre study**
N. Klimko (Saint Petersburg, Russian Federation), S. Khostelidi, V. Zaytsev, G. Evtukh, N. Nicitin, S. Vartanyan, E. Dulaeva, O. Shadrivova, O. Kozlova, U. Borzova, E. Desyatik, Bogomolova, Y. Avdeenko, M. Popova, L. Zubarovskaya*

P1564 **Prophylactic isavuconazole for invasive fungal infections: results from a systematic literature review**
Y. Ping (Beijing, China), J. Hongmei, C. Bellmann, M. Inês, T. Macmillan, N. Webb, J.A. Aram, O. Penack*

P1565 **Drug-drug interactions in patients treated for COVID-19-associated pulmonary aspergillosis: a review of queries to the COVID-19 interaction checker**
D. Burger (Nijmegen, Netherlands), C. Huijbers, A. Jansen, J. Chiong, S. Khoo, D. Back, M. Reijers, T. Frenzel, F. Van De Veerdonk, P. Pickkers, P. Verweij, R. Bruggemann*

P1566 ***In vitro* activity of manogepix against *Lomentospora prolificans, Scedosporium apiospermum, Pseudallescheria boydii* and other rare moulds**
L. Kirchhoff (Essen, Germany), S. Dittmer, P.M. Rath, J. Steinman, H.L. Verhasselt*

P1567 **Comparison of COVID-associated pulmonary aspergillosis and invasive aspergillosis in haematological patients**
N. Klimko (Saint Petersburg, Russian Federation), O. Shadrivova, D. Gusev, M. Vashukova, D. Lobzin, V. Gusarov, M. Zamyatin, A. Zavrazhnov, M. Mitichkin, O. Kozlova, E. Desyatik, E. Burygina, S. Ignatyeva, E. Oganesyan, O. Uspenskaya, S. Khostelidi, E. Shagdileeva, Y. Borzova, N. Vasilyeva*

P1568 **Plasma and cerebrospinal fluid (csf) concentrations of micafungin administered at high dosage in critically ill infants with systemic candidiasis**
C. Auriti (Rome, Italy), I. Bersani, D.U. De Rose, F. Piersigilli, S. Cairoli, A. Portanova, A. Dotta, A. Desai, L. Kovanda, P. Bagolan, B.M. Goffredo*

P1569 **Systemic antifungal therapy for esophageal candidiasis: systematic review and meta-analysis of randomised controlled trials**
A. Atamna (Petah Tikva, Israel), H. Atamna Mwassi, D. Yahav, G. Ayada, S. Matsri, I. Margalit, L. Shargian, J. Bishara*

P1570 **EQUAL *Trichosporon* Score: a ECMM score to measure quality of the clinical management of invasive *Trichosporon* infections**
R. Sprute (Cologne, Germany), O.A. Cornely*

P1571 **Safety and clinical outcomes associated with high-dose micafungin for proven invasive fungal disease**
V. Grant (Loma Linda, United States), K. Nguyen, S. Rodriguez, A. Zhou, J. Abdul-Mutakabbir, K. Tan*

P1572 **A porcine skin infection model to study novel treatments for fungal skin infections**
A. Bolhuis (Bath, United Kingdom), F.K.H. Ho, B. Delgado-Charro*

P1573 **Itraconazole reduces exacerbations in bronchiectasis with positive aspergillus serology/microbiology in the absence of asthma/ABPA**
C. Kosmidis (Manchester, United Kingdom), M. Vernon, A. Beech, A. Mathioudakis, C. Harris, D.W. Denning*

03315

The efficacy of ceragenins against first *Candida auris* strains isolated in Turkey

06. Fungal infection & disease

6c. Antifungal drugs & treatment (incl clinical trials)

Busra Alkan [1], Ozlem Oyardi [1], Selda Komec [2], Gonca Genc Erkose [3], Gokhan Aygun [4], Leyla Teke [5], Deniz Turan [6], Zayre Erturan [3], Paul Savage [7], Cagla Bozkurt Guzel [1]

[1]Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology - Istanbul (Turkey), [2]Basaksehir Cam and Sakura City Hospital, Laboratory of Medical Microbiology - Istanbul (Turkey), [3]Istanbul University Istanbul Faculty of Medicine, Department of Medical Microbiology - Istanbul (Turkey), [4]Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Medical Microbiology - Istanbul (Turkey), [5]University of Health Sciences Turkey, Gaziosmanpasa Training and Research Hospital, Clinic of Microbiology - Istanbul (Turkey), [6]University Of Health Sciences, Haydarpasa Numune Training and Research Hospital, Medical Microbiology Laboratory - Istanbul (Turkey), [7]Department of Chemistry and Biochemistry, Brigham Young University - Provo (United States)

Background Candida auris is a new emerging antifungal resistant pathogen leading to healthcare-associated infections and outbreaks. This fungus has shown resistance to polyenes, echinocandins, and azoles, especially fluconazole. It can be transmitted rapidly on hospital surfaces and medical devices. Ceragenins (Cationic Steroid Antibiotic-CSA) are cationic derivatives of colic acid, designed to mimic the activities of antimicrobial peptides, are a new class of antimicrobial agent. Ceragenins have broad antimicrobial activities including Candida spp. This study was aimed to investigate the antimicrobial activities of fluconazole, amphotericin B as conventional antifungals and CSA-13, CSA-44, CSA-131, CSA-138 as ceragenins against seven C. auris strains from Turkey.

Methods The antimicrobial activities of fluconazole, amphotericin B, CSA-13, CSA-44, CSA-131 and CSA-138 were studied against seven strains of C. auris isolated from different patients with candidemia in five hospitals in Turkey. MICs and MFCs were determined by microdilution method according to CLSI.

Results When the MIC values of all strains are evaluated according to CDC's temporary breakpoints for C. auris, (≥2 for amphotericin B, ≥32 for fluconazole) they are in the resistant category. According to the results, MIC values differ from 1 to 8 µg/ml for all CSAs. The most remarkable MIC values were shown by CSA-131 and 138: CSA-131 showed in the range of 2 to 4 µg/ml and CSA-138 showed 1 to 2 µg/ml. The results showed that ceragenins were effective against C. auris strains which were globally important threat. Especially, CSA-131 and CSA-138 showed the

lowest MIC values against all tested microorganisms. MFCs were found equal or twice greater than MICs.

Conclusions

Here, we present the first in vitro ceragenin study on C. auris strains isolated in Turkey. As a result, ceragenins especially CSA-131 and CSA-138 have significant antifungal effects against C. auris. But future studies should be performed to correlate safety, efficacy and pharmacokinetic parameters of these molecules.

Keyword 1
Candida auris
Keyword 2
Ceragenins
Keyword 3
Minimum Inhibitory Concentrations

Conflicts of interest

Do you have any conflicts of interest to declare?
I have no potential conflict of interest to report

Gmail özlem oyardı <ozlemyrd@gmail.com>

Fwd: 32nd ECCMID - Abstract submission

1 mesaj

Büşra Alkan <busraalkan17@gmail.com> 4 Nisan 2023 18:40
Alıcı: özlem oyardı <ozlemyrd@gmail.com>

Sent from my iPhone

Begin forwarded message:

From: 32nd European Congress of Clinical Microbiology & Infectious Diseases <eccmidinfo@escmid.org>
Date: 26 November 2021 12:51:13 GMT+3
To: busraalkan17@gmail.com
Subject: 32nd ECCMID - Abstract submission

32nd ECCMID EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES
Lisbon, Portugal
23–26 April 2022

26/11/2021

Dear Busra Alkan,

Thank you very much for submitting the abstract **The efficacy of ceragenins against first *Candida auris* strains isolated in Turkey** with abstract ID **03315** was submitted to ECCMID 2022 (32nd European Congress of Clinical Microbiology and Infectious Diseases).

Co-authors: Busra Alkan, Ozlem Oyardi, Selda Komec, Gonca Genc Erkose, Gokhan Aygun, Leyla Teke, Deniz Turan, Zayre Erturan, Paul Savage, Cagla Bozkurt Guzel,

Abstracts will be assessed by at least three reviewers in a blinded fashion and rated for scientific content, methodology, novelty, consistency of results and clarity of presentation. You will be informed around the end of January 2022 about the results of the abstract review and Programme Committee's decision regarding abstract acceptance and presentation type.

To view your abstract or submit a new abstract, please click here. Please note that images are displayed in small formatting to fit the A4 format but are stored in their original size on our server.

Yours sincerely,

ECCMID Abstract Team
c/o ESCMID Executive Office
Gerbergasse 14, 4001 Basel
Switzerland
Phone +41 61 508 01 59
Email : eccmidabstracts@escmid.org
www.eccmid.org

You received this email because you are the submitter of an abstract submitted to ECCMID 2022.
If you have any questions in regards to this, please contact the scientific secretariat at: eccmidinfo@escmid.org. Please quote your abstract number in the email subject line.

The efficacy of ceragenins against first Candida auris strains isolated in Turkey.pdf
71K